乌鸦传媒

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

A quarter of patients responded whether at the recommended or higher dose

Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients

Thirteen-month survival gain falls short of statistical significance in observational study

Numerical advantage in median survival, response rate, durability with dendritic-cell agent

Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors

Dramatic slowing of disease progression, prolonged responses with microbiome modulator

Present in roughly 5% of patients, survival worse in patients with larger or more lesions

Social media platform may be useful for trial recruitment, researchers say